Drug Trial Radar · NCT06708624
Ocular Safety and Usability Study for FYB201 PFS
Last checked: Nov 20, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Jun 11, 2024
Primary completion
Aug 8, 2024
Study completion Aug 8, 2024
Sponsor
- Lead sponsor
- Formycon AGIndustry
- Sponsor type
- Industry
- First posted
- Nov 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to assess the ocular safety of the FYB201 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.
Conditions
- Age-Related Macular Degeneration
- Branch Retinal Vein Occlusion with Macular Edema
- Central Retinal Vein Occlusion with Macular Edema
Interventions
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Drug
IVT administration of FYB201 in a PFS
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and occurrence of ocular and non-ocular Adverse Events (AEs) and Serious Adverse Events (SAEs) occurring after IVT injectionTime frame: 2 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Campbell, California
Research Site
Long Beach, California
Research Site
Hagerstown, Maryland
Research Site
Eugene, Oregon
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.